Asimadoline, a kappa‐opioid agonist, and satiation in functional dyspepsia
NJ Talley, RS Choung, M Camilleri… - Alimentary …, 2008 - Wiley Online Library
NJ Talley, RS Choung, M Camilleri, RA Dierkhising, AR Zinsmeister
Alimentary pharmacology & therapeutics, 2008•Wiley Online LibraryBackground Asimadoline, a kappa‐opioid agonist, reduces visceral sensitivity in
experimental animal models and may decrease satiation and postprandial fullness in
healthy individuals. However, its effect on satiation in functional dyspepsia is unclear, and
any symptom benefit has not been explored. Aim To evaluate the effects of asimadoline on
satiation volume and postchallenge symptoms in functional dyspepsia. Methods A
randomized, double‐blind trial evaluated gastric satiation and symptoms before and after 8 …
experimental animal models and may decrease satiation and postprandial fullness in
healthy individuals. However, its effect on satiation in functional dyspepsia is unclear, and
any symptom benefit has not been explored. Aim To evaluate the effects of asimadoline on
satiation volume and postchallenge symptoms in functional dyspepsia. Methods A
randomized, double‐blind trial evaluated gastric satiation and symptoms before and after 8 …
Summary
Background Asimadoline, a kappa‐opioid agonist, reduces visceral sensitivity in experimental animal models and may decrease satiation and postprandial fullness in healthy individuals. However, its effect on satiation in functional dyspepsia is unclear, and any symptom benefit has not been explored.
Aim To evaluate the effects of asimadoline on satiation volume and postchallenge symptoms in functional dyspepsia.
Methods A randomized, double‐blind trial evaluated gastric satiation and symptoms before and after 8 weeks of asimadoline 0.5 mg (n = 13) or 1.0 mg (n = 13) or placebo (n = 14) b.d. in patients with functional dyspepsia (Rome II). Gastrointestinal Symptom Rating Scale and Nepean Dyspepsia Index were used to assess symptoms during the 8‐week treatment.
Results Over 8 weeks of treatment, asimadoline had no significant effect on maximum‐tolerated volume or aggregate symptom score with nutrient drink challenge, and on the mean of the total daily symptom severity score compared to placebo. In a post hoc analysis, asimadoline 0.5 mg significantly increased the maximum‐tolerated volume (1217 mL ± 90.2) compared to placebo (807 mL ± 111.8) in patients with higher postprandial fullness scores (P = 0.01).
Conclusion Asimadoline overall did not significantly alter maximum‐tolerated volume, symptoms postnutrient challenge or symptoms over 8 weeks in functional dyspepsia.
Wiley Online Library